学术报告：Unleashing T Cell Activity for Targeted Immunotherapy of Acute Myeloid Leukemia
报告题目：Unleashing T Cell Activity for Targeted Immunotherapy of Acute Myeloid Leukemia
报 告 人：吕华研究员（北京大学）
报告时间：2014年8月26日 上午10：30
报告地点：嘉定园区学术活动中心307室
Abstract:
Acute myeloid leukemia (AML), the most common acute adult leukemia and the second most common pediatric leukemia, currently remains incurable with a poor prognosis. Human C-type lectin-like molecule-1 (CLL1) is a recently identified myeloid lineage restricted cell surface marker, which is overexpressed in over 90% of AML patient myeloid blasts and in leukemic stem cells. In this talk, I will overview clinical efforts and strategies on antibody related therapeutics for cancers, with particular emphasis on cancer immunotherapy. I will then discuss the synthesis of a novel bispecific antibody, αCLL1-αCD3, using the genetically encoded unnatural amino acid, and its application as a T cell engager for AML treatment.
吕华中文简历.pdf
相关附件